Form 4: AnaptysBio Director Exercises Stock Options Nearing Expiration

John P. Schmid, a director at AnaptysBio, Inc., exercised stock options expiring in 2025, acquiring a total of 42,337 shares of common stock.

Summary

• On January 13, 2025, John P. Schmid, a director of AnaptysBio, Inc., exercised stock options to acquire 21,692 shares of common stock at $4.55 per share and 20,645 shares at $8.54 per share.
• These stock options were set to expire in 2025, prompting the director to exercise them.
• Following these transactions, Schmid directly owns 46,237 shares of AnaptysBio common stock.
• The director does not currently intend to sell any of the exercised shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction. The director exercising options before expiration is a standard practice.

Positives

• The director's exercise of options demonstrates confidence in the company's future.

Future Outlook

The director does not intend to currently sell any of the exercised shares.

Management Comments

• The exercises reported on this Form 4 for various stock options are expiring in 2025 and the Reporting Person wished to facilitate the exercises of such options before their expiration.
• The Reporting Person does not intend to currently sell any of the said exercised shares in this Form 4.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like directors, buy or sell company stock. These filings provide transparency to the market.

Stakeholder Impact

• The exercise of stock options by a director could be viewed positively by shareholders as it indicates confidence in the company.

Key Dates